Trials / Recruiting
RecruitingNCT04354064
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Conditions
- Healthy Volunteer
- Prostate Cancer
- Head and Neck Cancer
- Esophageal Cancer
- Genitourinary Cancer
- Sarcoma
- Breast Cancer
- Colon Cancer
- Gastrointestinal Cancer
- Solid Tumor Cancer
- Lung Cancer
- Skin Cancer
- Melanoma
Timeline
- Start date
- 2019-05-29
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2020-04-21
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04354064. Inclusion in this directory is not an endorsement.